Estradiol .05 mg/d

Estradiol, the active ingredient in Estradiol .05 mg/d, is an estrogen presented as a 0.05 mg/day transdermal patch for transdermal use. It is used to treat moderate to severe vasomotor symptoms associated with menopause, prevent osteoporosis in postmenopausal women, and treat hypoestrogenism due to ovarian failure or hypogonadism.

GNH USA supplies Estradiol .05 mg/d as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Estradiol .05 mg/d is a hormone replacement therapy used to manage conditions related to estrogen deficiency.

- Moderate to severe vasomotor symptoms due to menopause: Reduces hot flashes and night sweats. - Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause: Alleviates vaginal dryness, itching, and burning. - Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure: Restores estrogen levels. - Prevention of postmenopausal osteoporosis: Helps maintain bone density in women at significant risk of osteoporosis.

Estradiol .05 mg/d may cause side effects, ranging from common to serious or rare.

Common Side Effects: - Redness or irritation at the application site. - Breast tenderness or swelling. - Headache. - Nausea. - Abdominal bloating. - Breakthrough bleeding or spotting.

Serious or Rare Side Effects: - Increased risk of endometrial cancer (in women with a uterus). - Increased risk of breast cancer. - Venous thromboembolism (blood clots). - Stroke or heart attack. - Gallbladder disease. - Dementia (in postmenopausal women over 65).

Estradiol .05 mg/d should be used with caution and under medical supervision.

- Prescribing: Use the lowest effective dose and shortest duration consistent with treatment goals. - Monitoring: Regularly reevaluate the need for continued therapy. - Contraindications: Do not use in individuals with undiagnosed abnormal vaginal bleeding, known or suspected estrogen-dependent neoplasms, or active deep vein thrombosis. - Progestogen: Generally, a progestogen should be added to reduce the risk of endometrial cancer in women with a uterus. - Storage: Store at 20 to 25°C (68 to 77°F); excursions permitted to 15 to 30°C (59 to 86°F). Do not store unpouched. Apply immediately upon removal from the protective pouch.

Estradiol .05 mg/d may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Anticoagulants: Increased risk of bleeding. - CYP3A4 inducers: May decrease estradiol effectiveness. - Tamoxifen: May reduce the effectiveness of tamoxifen.

Moderate Interactions (Monitor Closely): - Anticonvulsants: May alter estradiol metabolism. - Corticosteroids: May reduce estradiol effectiveness. - Thyroid hormones: May require dose adjustment of thyroid hormones.